| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
long-term use of clozapine is protective for bone density in patients with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
previous cross-section study suggests that clozapine treatment may benefit bmd of women with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
this prospective study compared clozapine and non-clozapine antipsychotics in long-term effects on bmd among both men and women with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Chun-Yuan Lin, Hong-Song Wang, Hsien-Yuan Lan. Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific reports. vol 9. issue 1. 2020-09-23. PMID:30846868. |
this longitudinal study suggests that long-term clozapine treatment may protect bmd compared to prolactin-raising and non-clozapine prolactin-sparing antipsychotics among patients with schizophrenia. |
2020-09-23 |
2023-08-13 |
Not clear |
| Dan Siskind, Faraz Honarparvar, Alkomiet Hasan, Elias Wagner, Surabhi Sinha, Stacy Orr, Steve Kisel. rTMS for clozapine refractory schizophrenia - A systematic review and pairwise meta-analysis. Schizophrenia research. vol 211. 2020-09-22. PMID:31301880. |
rtms for clozapine refractory schizophrenia - a systematic review and pairwise meta-analysis. |
2020-09-22 |
2023-08-13 |
Not clear |
| Sakir Gica, Ahsen Buyukavsar, Burc Cagri Poyraz, Huseyin Gule. The clinical correlation and predictive value of electrophysiological variables on clinical response to clozapine in patients with treatment-resistant schizophrenia. Schizophrenia research. vol 211. 2020-09-21. PMID:31331783. |
the clinical correlation and predictive value of electrophysiological variables on clinical response to clozapine in patients with treatment-resistant schizophrenia. |
2020-09-21 |
2023-08-13 |
Not clear |
| Orwa Albitar, Sabariah Noor Harun, Hadzliana Zainal, Baharudin Ibrahim, Siti Maisharah Sheikh Ghadz. Population Pharmacokinetics of Clozapine: A Systematic Review. BioMed research international. vol 2020. 2020-09-21. PMID:31998804. |
clozapine is a second-generation antipsychotic drug that is considered the most effective treatment for refractory schizophrenia. |
2020-09-21 |
2023-08-13 |
Not clear |
| V V Kravtsov, I A Filippov, E E Vaiman, N A Shnayder, R F Nasyrov. [Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 120. issue 7. 2020-09-17. PMID:32790988. |
a systematic review of association studies on the role of single nucleotide variants (snvs) of the dopaminergic system genes on the effectiveness of clozapine in schizophrenia has been perfromed. |
2020-09-17 |
2023-08-13 |
Not clear |
| Piotr Jahołkowski, Julita Niewiadomska, Jacek Wciórka, Mirosław Kowalski, Piotr Świta. Clozapine-induced myocarditis during co-administration of valproate: A case report. Psychiatria polska. vol 53. issue 5. 2020-09-16. PMID:31955181. |
in this paper, we present a case of a 22-year-old male patient with refractory schizophrenia who developed cimduring low-dose clozapine treatment with co-administration of valproate and risperidone. |
2020-09-16 |
2023-08-13 |
Not clear |
| Mark James Ponsford, Rachael Steven, Kathyrn Bramhall, Mathew Burgess, Sonali Wijetilleka, Emily Carne, Frances McGuire, Colin R Price, Mo Moody, Soha Zouwail, Tayyeb Tahir, Daniel Farewell, Tariq El-Shanawany, Stephen R A Jolle. Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID). Journal of clinical pathology. vol 73. issue 9. 2020-08-31. PMID:32094276. |
an association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. |
2020-08-31 |
2023-08-13 |
Not clear |
| Thinh Nguyen, Jasmine Mordecai, Felice Watt, Jacqueline Frayn. Obstetric and neonatal outcomes of clozapine exposure in pregnancy: a consecutive case series. Archives of women's mental health. vol 23. issue 3. 2020-08-25. PMID:31203441. |
clozapine is an effective antipsychotic that can lead to symptom resolution and functional recovery in patients with schizophrenia. |
2020-08-25 |
2023-08-13 |
Not clear |
| Rajendra P Shukla, Hadar Ben-Yoa. A Chitosan-Carbon Nanotube-Modified Microelectrode for In Situ Detection of Blood Levels of the Antipsychotic Clozapine in a Finger-Pricked Sample Volume. Advanced healthcare materials. vol 8. issue 15. 2020-08-19. PMID:31240866. |
the antipsychotic clozapine is the most effective medication available for schizophrenia and it is the only antipsychotic with a known efficacious clinical range. |
2020-08-19 |
2023-08-13 |
human |
| Emily C Amador, Jendayi L Olabisi, Elizabeth A Cunningha. Schizophrenia With Decompensation on Clozapine With Pramipexole. The primary care companion for CNS disorders. vol 21. issue 6. 2020-08-18. PMID:31877244. |
schizophrenia with decompensation on clozapine with pramipexole. |
2020-08-18 |
2023-08-13 |
Not clear |
| Elias Wagner, Thomas Wobrock, Birgit Kunze, Berthold Langguth, Michael Landgrebe, Peter Eichhammer, Elmar Frank, Joachim Cordes, Wolfgang Wölwer, Georg Winterer, Wolfgang Gaebel, Göran Hajak, Christian Ohmann, Pablo E Verde, Marcella Rietschel, Raees Ahmed, William G Honer, Dan Siskind, Berend Malchow, Wolfgang Strube, Thomas Schneider-Axmann, Peter Falkai, Alkomiet Hasa. Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. Schizophrenia research. vol 208. 2020-08-17. PMID:30704862. |
efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. |
2020-08-17 |
2023-08-13 |
Not clear |
| Katherine Beck, Robert McCutcheon, Lucy Stephenson, Marcela Schilderman, Natasha Patel, Rosalind Ramsay, Oliver D Howe. Prevalence of treatment-resistant psychoses in the community: A naturalistic study. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31241396. |
however, the rate of treatment resistance among outpatients with schizophrenia or other psychoses, and the rate of use of clozapine among them, is not known. |
2020-08-17 |
2023-08-13 |
Not clear |
| Parnian Pardis, Gary Remington, Roshni Panda, Milan Lemez, Ofer Agi. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. Journal of psychopharmacology (Oxford, England). vol 33. issue 10. 2020-08-17. PMID:31347436. |
clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. |
2020-08-17 |
2023-08-13 |
Not clear |
| Seoyoung Kim, Wi Hoon Jung, Oliver D Howes, Mattia Veronese, Federico E Turkheimer, Yun-Sang Lee, Jae Sung Lee, Euitae Kim, Jun Soo Kwo. Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [ Psychological medicine. vol 49. issue 15. 2020-08-05. PMID:30460891. |
thus, the aim of this study was to investigate the relationship between frontostriatal fc and striatal dopamine synthesis capacity in patients with schizophrenia who had responded to first-line antipsychotic drug compared with those who had failed but responded to clozapine. |
2020-08-05 |
2023-08-13 |
Not clear |
| Jose de Leon, Can-Jun Ruan, Georgios Schoretsanitis, Carlos De Las Cueva. A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology. Psychotherapy and psychosomatics. vol 89. issue 4. 2020-07-17. PMID:32289791. |
using richardson and davidson's model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (trs), which may be improved in patients who adhere to clozapine; (2) findings that clozapine is the best treatment for trs (according to efficacy, effectiveness and well-being); and (3) potential for clozapine to cause vulnerabilities, including potentially lethal adverse drug reactions such as agranulocytosis, pneumonia, and myocarditis. |
2020-07-17 |
2023-08-13 |
Not clear |
| N Bouaziz, H Ben Rejeb, S Ateb, T Fourati, F Chammas, D Baha, R Rosetti, K Kalalou, G Saba, R Benadhira, D Janue. [Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate]. L'Encephale. vol 46. issue 3S. 2020-07-17. PMID:32475694. |
[thoughts on a favourable evolution of a covid-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate]. |
2020-07-17 |
2023-08-13 |
Not clear |
| Shih-Yu Chen, Gopi Ravindran, Qichen Zhang, Steve Kisely, Dan Siskin. Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis. CNS drugs. vol 33. issue 3. 2020-07-02. PMID:30758782. |
clozapine is the most effective medication for treatment-refractory schizophrenia. |
2020-07-02 |
2023-08-13 |
Not clear |